Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mali Jiang is active.

Publication


Featured researches published by Mali Jiang.


Nature Medicine | 2012

Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets

Mali Jiang; Jiawei Wang; Jinrong Fu; Lin Du; Hyunkyung Jeong; Tim West; Lan Xiang; Qi Peng; Zhipeng Hou; Huan Cai; Tamara Seredenina; Nicolas Arbez; Shanshan Zhu; Katherine Sommers; Jennifer Qian; Jiangyang Zhang; Susumu Mori; X. William Yang; Kellie L.K. Tamashiro; Susan Aja; Timothy H. Moran; Ruth Luthi-Carter; Bronwen Martin; Stuart Maudsley; Mark P. Mattson; Robert H. Cichewicz; Christopher A. Ross; David M. Holtzman; Dimitri Krainc; Wenzhen Duan

Huntingtons disease is a fatal neurodegenerative disorder caused by an expanded polyglutamine repeat in huntingtin (HTT) protein. We previously showed that calorie restriction ameliorated Huntingtons disease pathogenesis and slowed disease progression in mice that model Huntingtons disease (Huntingtons disease mice). We now report that overexpression of sirtuin 1 (Sirt1), a mediator of the beneficial metabolic effects of calorie restriction, protects neurons against mutant HTT toxicity, whereas reduction of Sirt1 exacerbates mutant HTT toxicity. Overexpression of Sirt1 improves motor function, reduces brain atrophy and attenuates mutant-HTT–mediated metabolic abnormalities in Huntingtons disease mice. Further mechanistic studies suggested that Sirt1 prevents the mutant-HTT–induced decline in brain-derived neurotrophic factor (BDNF) concentrations and the signaling of its receptor, TrkB, and restores dopamine- and cAMP-regulated phosphoprotein, 32 kDa (DARPP32) concentrations in the striatum. Sirt1 deacetylase activity is required for Sirt1-mediated neuroprotection in Huntingtons disease cell models. Notably, we show that mutant HTT interacts with Sirt1 and inhibits Sirt1 deacetylase activity, which results in hyperacetylation of Sirt1 substrates such as forkhead box O3A (Foxo3a), thereby inhibiting its pro-survival function. Overexpression of Sirt1 counteracts the mutant-HTT–induced deacetylase deficit, enhances the deacetylation of Foxo3a and facilitates cell survival. These findings show a neuroprotective role for Sirt1 in mammalian Huntingtons disease models and open new avenues for the development of neuroprotective strategies in Huntingtons disease.


Experimental Neurology | 2008

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model

Qi Peng; Naoki Masuda; Mali Jiang; Qing Li; Ming Zhao; Christopher A. Ross; Wenzhen Duan

Huntingtons disease (HD) is an inherited progressive neurodegenerative disorder characterized by progressive movement, psychiatric and cognitive disturbances. Previous studies have indicated that HD pathogenesis may be mediated in part by loss of brain derived neurotrophic factor (BDNF). Antidepressants selectively blocking serotonin reuptake can increase BDNF levels, and also may increase neurogenesis. Here we report that an SSRI antidepressant, sertraline, prolongs survival, improves motor performance, and ameliorates brain atrophy in the R6/2 HD mouse model. Six-week-old R6/2 mice and nontransgenic control mice were administered either sertraline or vehicle daily. Motor function was assessed in an accelerating rotarod test and evaluated at 10 weeks. R6/2 mice exhibited reduced time on the rod. Sertraline treatment improved the motor performance in R6/2 mice, but did not affect nontransgenic mice. R6/2 mice showed significant striatal atrophy which was reduced by sertraline treatment. These beneficial effects of sertraline are associated with enhanced neurogenesis and increased BDNF levels in brain treated with sertraline. The effective serum and brain levels of sertraline are comparable to the levels achieved in human antidepressant treatment. Our findings provide evidence that sertraline is neuroprotective in this HD model. Successful treatment with sertraline in depressed HD patients has been reported; moreover, sertraline is safe and well-tolerated for long-term administration, including in HD patients. Our findings suggest that a clinical trial of SSRI treatment in order to retard disease progression in human HD may be warranted.


Journal of Biological Chemistry | 2012

trans-(-)-ε-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease.

Jinrong Fu; Jing Jin; Robert H. Cichewicz; Serena A. Hageman; Trevor K. Ellis; Lan Xiang; Qi Peng; Mali Jiang; Nicolas Arbez; Katelyn Hotaling; Christopher A. Ross; Wenzhen Duan

Background: Mitochondrial dysfunction is a key event mediating mutant Htt-induced neurotoxicity. Results: trans-(−)-ϵ-Viniferin attenuates mutant Htt-induced SIRT3 depletion, activates AMPK, and preserves mitochondrial function. Conclusion: Increasing SIRT3 protects cells in HD. Significance: The result suggests a promising new target for development of HD therapeutics. Huntington disease (HD) is an inherited neurodegenerative disorder caused by an abnormal polyglutamine expansion in the protein Huntingtin (Htt). Currently, no cure is available for HD. The mechanisms by which mutant Htt causes neuronal dysfunction and degeneration remain to be fully elucidated. Nevertheless, mitochondrial dysfunction has been suggested as a key event mediating mutant Htt-induced neurotoxicity because neurons are energy-demanding and particularly susceptible to energy deficits and oxidative stress. SIRT3, a member of sirtuin family, is localized to mitochondria and has been implicated in energy metabolism. Notably, we found that cells expressing mutant Htt displayed reduced SIRT3 levels. trans-(−)-ϵ-Viniferin (viniferin), a natural product among our 22 collected naturally occurring and semisynthetic stilbenic compounds, significantly attenuated mutant Htt-induced depletion of SIRT3 and protected cells from mutant Htt. We demonstrate that viniferin decreases levels of reactive oxygen species and prevents loss of mitochondrial membrane potential in cells expressing mutant Htt. Expression of mutant Htt results in decreased deacetylase activity of SIRT3 and further leads to reduction in cellular NAD+ levels and mitochondrial biogenesis in cells. Viniferin activates AMP-activated kinase and enhances mitochondrial biogenesis. Knockdown of SIRT3 significantly inhibited viniferin-mediated AMP-activated kinase activation and diminished the neuroprotective effects of viniferin, suggesting that SIRT3 mediates the neuroprotection of viniferin. In conclusion, we establish a novel role for mitochondrial SIRT3 in HD pathogenesis and discovered a natural product that has potent neuroprotection in HD models. Our results suggest that increasing mitochondrial SIRT3 might be considered as a new therapeutic approach to counteract HD, as well as other neurodegenerative diseases with similar mechanisms.


NeuroImage | 2010

Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images

Jiangyang Zhang; Qi Peng; Qing Li; Neda Jahanshad; Zhipeng Hou; Mali Jiang; Naoki Masuda; Douglas R. Langbehn; Michael I. Miller; Susumu Mori; Christopher A. Ross; Wenzhen Duan

Mouse models of human diseases play crucial roles in understanding disease mechanisms and developing therapeutic measures. Huntingtons disease (HD) is characterized by striatal atrophy that begins long before the onset of motor symptoms. In symptomatic HD, striatal volumes decline predictably with disease course. Thus, imaging based volumetric measures have been proposed as outcomes for presymptomatic as well as symptomatic clinical trials of HD. Magnetic resonance imaging of the mouse brain structures is becoming widely available and has been proposed as one of the biomarkers of disease progression and drug efficacy testing. However, three-dimensional and quantitative morphological analyses of the brains are not straightforward. In this paper, we describe a tool for automated segmentation and voxel-based morphological analyses of the mouse brains. This tool was applied to a well-established mouse model of Huntingtons disease, the R6/2 transgenic mouse strain. Comparison between the automated and manual segmentation results showed excellent agreement in most brain regions. The automated method was able to sensitively detect atrophy as early as 4 weeks of age and accurately follow disease progression. Comparison between ex vivo and in vivo MRI suggests that the ex vivo end-point measurement of brain morphology is also a valid approach except for the morphology of the ventricles. This is the first report of longitudinal characterization of brain atrophy in a mouse model of Huntingtons disease by using automatic morphological analysis.


Journal of Neurochemistry | 2010

Baicalein reduces E46K α‐synuclein aggregation in vitro and protects cells against E46K α‐synuclein toxicity in cell models of familiar Parkinsonism

Mali Jiang; Yair Porat-Shliom; Zhong Pei; Yong Cheng; Lan Xiang; Katherine Sommers; Qing Li; Bastian Hengerer; Cynthia Berlinicke; Wanli W. Smith; Donald J. Zack; Michelle A. Poirier; Christopher A. Ross; Wenzhen Duan

J. Neurochem. (2010) 114, 419–429.


The Journal of Neuroscience | 2012

Transgenic Mouse Model Expressing the Caspase 6 Fragment of Mutant Huntingtin

Elaine Waldron-Roby; Tamara Ratovitski; Xiaofang Wang; Mali Jiang; Erin E. Watkin; Nikolas Arbez; Rona K. Graham; Michael R. Hayden; Zhipeng Hou; Susumu Mori; Deborah A. Swing; Mikhail V. Pletnikov; Wenzhen Duan; Lino Tessarollo; Christopher A. Ross

Huntingtons disease (HD) is caused by a polyglutamine expansion in the Huntingtin (Htt) protein. Proteolytic cleavage of Htt into toxic N-terminal fragments is believed to be a key aspect of pathogenesis. The best characterized putative cleavage event is at amino acid 586, hypothesized to be mediated by caspase 6. A corollary of the caspase 6 cleavage hypothesis is that the caspase 6 fragment should be a toxic fragment. To test this hypothesis, and further characterize the role of this fragment, we have generated transgenic mice expressing the N-terminal 586 aa of Htt with a polyglutamine repeat length of 82 (N586–82Q), under the control of the prion promoter. N586–82Q mice show a clear progressive rotarod deficit by 4 months of age, and are hyperactive starting at 5 months, later changing to hypoactivity before early mortality. MRI studies reveal widespread brain atrophy, and histologic studies demonstrate an abundance of Htt aggregates, mostly cytoplasmic, which are predominantly composed of the N586–82Q polypeptide. Smaller soluble N-terminal fragments appear to accumulate over time, peaking at 4 months, and are predominantly found in the nuclear fraction. This model appears to have a phenotype more severe than current full-length Htt models, but less severe than HD mouse models expressing shorter Htt fragments. These studies suggest that the caspase 6 fragment may be a transient intermediate, that fragment size is a factor contributing to the rate of disease progression, and that short soluble nuclear fragments may be most relevant to pathogenesis.


Neurobiology of Disease | 2008

Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.

Naoki Masuda; Qi Peng; Qing Li; Mali Jiang; Yideng Liang; Xiaofang Wang; Ming Zhao; Wenfei Wang; Christopher A. Ross; Wenzhen Duan

Huntingtons disease (HD) is an autosomal dominant neurodegenerative disorder characterized by chorea, incoordination, and shortened life-span, and by huntingtin inclusions and neurodegeneration. We previously screened the 1040 FDA-approved compounds from the NINDS compound library and found that a compound, nipecotic acid, significantly reduced mutant huntingtin aggregations and blocked cell toxicity in an inducible cell model of HD. Because nipecotic acid does not cross the blood-brain barrier (BBB), we studied its analogue, tiagabine, which is able to cross the BBB, in both N171-82Q and R6/2 transgenic mouse models of HD. Tiagabine was administered intraperitoneally at 2 and 5 mg/kg daily in HD mice. We found that tiagabine extended survival, improved motor performance, and attenuated brain atrophy and neurodegeneration in N171-82Q HD mice. These beneficial effects were further confirmed in R6/2 HD mice. The levels of tiagabine at effective doses in mouse serum are comparable to the levels in human patients treated with tiagabine. These results suggest that tiagabine may have beneficial effects in the treatment of HD. Because tiagabine is an FDA-approved drug, it may be a promising candidate for future clinical trials for the treatment of HD.


Human Molecular Genetics | 2015

Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease

Jing Jin; Qi Peng; Zhipeng Hou; Mali Jiang; Xin Wang; Abraham J. Langseth; Michael Tao; Peter B. Barker; Susumu Mori; Dwight E. Bergles; Christopher A. Ross; Peter J. Detloff; Jiangyang Zhang; Wenzhen Duan

White matter abnormalities have been reported in premanifest Huntingtons disease (HD) subjects before overt striatal neuronal loss, but whether the white matter changes represent a necessary step towards further pathology and the underlying mechanism of these changes remains unknown. Here, we characterized a novel knock-in mouse model that expresses mouse HD gene homolog (Hdh) with extended CAG repeat- HdhQ250, which was derived from the selective breeding of HdhQ150 mice. HdhQ250 mice manifest an accelerated and robust phenotype compared with its parent line. HdhQ250 mice exhibit progressive motor deficits, reduction in striatal and cortical volume, accumulation of mutant huntingtin aggregation, decreased levels of DARPP32 and BDNF and altered striatal metabolites. The abnormalities detected in this mouse model are reminiscent of several aspects of human HD. In addition, disturbed myelination was evident in postnatal Day 14 HdhQ250 mouse brain, including reduced levels of myelin regulatory factor and myelin basic protein, and decreased numbers of myelinated axons in the corpus callosum. Thinner myelin sheaths, indicated by increased G-ratio of myelin, were also detected in the corpus callosum of adult HdhQ250 mice. Moreover, proliferation of oligodendrocyte precursor cells is altered by mutant huntingtin both in vitro and in vivo. Our data indicate that this model is suitable for understanding comprehensive pathogenesis of HD in white matter and gray matter as well as developing therapeutics for HD.


Annals of clinical and translational neurology | 2014

Sirtuin 1 activator SRT2104 protects Huntington's disease mice

Mali Jiang; Jennifer Zheng; Qi Peng; Zhipeng Hou; Jiangyang Zhang; Susumu Mori; James L. Ellis; George P. Vlasuk; Harvey Fries; Vipin Suri; Wenzhen Duan

Sirtuin 1 is a nicotinamide adenine dinucleotide‐dependent protein deacetylase which regulates longevity and improves metabolism. Activation of Sirtuin 1 confers beneficial effects in models of neurodegenerative diseases. We and others have provided convincing evidence that overexpression of Sirtuin 1 plays a neuroprotective role in mouse models of Huntingtons disease. In this study, we report that SRT2104, a small molecule Sirtuin 1 activator, penetrated the blood–brain barrier, attenuated brain atrophy, improved motor function, and extended survival in a mouse model of Huntingtons disease. These findings imply a novel therapeutic strategy for Huntingtons disease by targeting Sirtuin 1.


Movement Disorders | 2014

Metabolism in HD: Still a relevant mechanism?

Wenzhen Duan; Mali Jiang; Jing Jin

The polyglutamine expansion within huntingtin is the causative factor in the pathogenesis of Huntingtons disease (HD). Although the underlying mechanisms by which mutant huntingtin causes neuronal dysfunction and degeneration have not been fully elucidated, compelling evidence suggests that mitochondrial dysfunction and compromised energy metabolism are key players in HD pathogenesis. Longitudinal studies of HD subjects have shown reductions in glucose utilization before the disease clinical onset. Preferential striatal neurodegeneration, a hallmark of HD pathogenesis, also has been associated with interrupted energy metabolism. Data from genetic HD models indicate that mutant huntingtin disrupts mitochondrial bioenergetics and prevents adenosine triphosphate (ATP) generation, implying altered energy metabolism as an important component of HD pathogenesis. Here we revisit the evidence of abnormal energy metabolism in the central nervous system of HD patients, review our current understanding of the molecular mechanisms underlying abnormal metabolism induced by mutant huntingtin, and discuss the promising therapeutic development by halting abnormal metabolism in HD.

Collaboration


Dive into the Mali Jiang's collaboration.

Top Co-Authors

Avatar

Wenzhen Duan

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Qi Peng

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Christopher A. Ross

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Zhipeng Hou

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Susumu Mori

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Jiangyang Zhang

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Jing Jin

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Nicolas Arbez

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Qing Li

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Naoki Masuda

Johns Hopkins University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge